RedHill Biopharma Ltd.
http://www.redhillbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From RedHill Biopharma Ltd.
Grünenthal Bolsters US Portfolio With Buyout Of Valinor
Deal snapshot: The German pain-management specialist is acquiring Valinor to gain additional geographic rights to the gastrointestinal drug Movantik and add to its US product portfolio.
Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna
Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.
Finance Watch: Public Market Doldrums Have Not Sunk Private Company Funding Yet
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
Coronavirus Notebook: UK Reports Impressive Booster Results, Drones Deliver Vaccines In Africa
Emergex is preparing to begin a Phase I study of its T-cell priming vaccine, RedHill BioPharma has completed enrolment in a Phase II/III study of upamostat, and Australia is assessing Moderna’s Spikevax for use in 6-11 year olds.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice